ArticleBMC cancer2019

Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.

Piya Rujkijyanont et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.